Clearmind Medicine Gets IRB Approval for AUD Trial
Ticker: CMND · Form: 6-K · Filed: Jul 3, 2025 · CIK: 1892500
Sentiment: bullish
Topics: clinical-trial, healthcare, drug-development, regulatory-approval
TL;DR
Clearmind Medicine just got the green light for its Phase 1/2a AUD trial at Tel Aviv Sourasky Medical Center. Big step for their drug.
AI Summary
Clearmind Medicine Inc. announced on July 3, 2025, that it has received Institutional Review Board (IRB) approval for a Phase 1/2a clinical trial. This trial will investigate the efficacy of its novel treatment for Alcohol Use Disorder (AUD) at Tel Aviv Sourasky Medical Center.
Why It Matters
This IRB approval is a critical step forward, allowing Clearmind Medicine to begin clinical testing of its potential treatment for Alcohol Use Disorder, a significant public health issue.
Risk Assessment
Risk Level: medium — Clinical trial approvals are positive, but the success of the trial and subsequent regulatory approvals are not guaranteed, carrying inherent risks.
Key Players & Entities
- Clearmind Medicine Inc. (company) — Registrant
- July 3, 2025 (date) — Announcement date
- Tel Aviv Sourasky Medical Center (company) — Location of clinical trial
- Alcohol Use Disorder (condition) — Indication being studied
FAQ
What is the purpose of the clinical trial announced by Clearmind Medicine?
The clinical trial is a Phase 1/2a study to investigate the efficacy of Clearmind Medicine's novel treatment for Alcohol Use Disorder (AUD).
Where will the clinical trial be conducted?
The clinical trial will be conducted at Tel Aviv Sourasky Medical Center.
What is the significance of the IRB approval?
The IRB approval signifies that the Institutional Review Board has reviewed and approved the protocol for the clinical trial, allowing it to proceed.
What type of disorder is Clearmind Medicine targeting with its treatment?
Clearmind Medicine is targeting Alcohol Use Disorder (AUD) with its novel treatment.
When was this announcement made?
The announcement was made on July 3, 2025, as part of a Form 6-K filing.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on July 3, 2025 regarding Clearmind Medicine Inc. (CMND).